Navigation Links
HART's CMO Dr. Saverio La Francesca to moderate panel on "Regenerative Engineering and Bio-Materials" at World Stem Cell Summit Saturday, Dec. 12
Date:12/8/2015

ATLANTA and HOLLISTON, Mass., Dec. 8, 2015 /PRNewswire/ -- Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions, today announced that Executive Vice President and Chief Medical Officer Saverio La Francesca, MD will moderate and speak at the World Stem Cell Summit during a secession entitled "Regenerative Engineering and Bio-Materials" on Saturday, December 12, 2015 at 2:00 p.m. ET. The conference will be held at the Hyatt Regency in Atlanta, GA. 

HART's cell frame technology utilizes the patient's own stem cells combined with its proprietary scaffold to restore organ function in the airways and esophagus. HART recently reported significant improvements in their Gen2 product implants.

About Dr. Saverio La Francesca:
Dr. La Francesca is a cardiothoracic surgeon with over 25 years of academic, clinical surgical practice and innovative research, in the cardiovascular, thoracic transplantation, cardiac assist device and regenerative medicine fields. Previously he worked with the Dept. of Cardiovascular Surgery and Transplantation at DeBakey Heart and Vascular Center at the Houston Methodist Hospital, where he developed the current surgical and perfusion techniques for thoracic organ procurement and preservation. He was also an attending surgeon at the Department of Cardiopulmonary Transplantation at the Texas Heart Institute in Houston, Texas. Dr. La Francesca holds UNOS certifications as heart transplant surgeon and lung transplant surgeon and is a certified surgeon for the use of the HeartMate and the Jarvik 2000 left ventricular assist devices.

About World Stem Cell Summit (worldstemcellsummit.com)
The World Stem Cell Summit, produced by the Genetics Policy Institute (GPI), is the largest interdisciplinary, networking meeting of stem cell science and regenerative medicine stakeholders, uniting the diverse community. With the overarching purpose of fostering biomedical research, funding and investments targeting cures, the Summit is the single conference charting the future of this burgeoning field. Featuring more than 200 renowned international speakers and 65 hours of in-depth programming, the World Stem Cell Summit unites, educates, and harmonizes the global stem cell community.

About HART: (www.hartregen.com)
Harvard Apparatus Regenerative Technology (HART) makes bioengineered organ implants for life-threatening conditions. Our technology platform is to be used to restore function in the esophagus and the airways (trachea and bronchus). HART is completing further large-animal studies to refine our technology platform with the goal of filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration in 2016, seeking to initiate clinical trials for one of our three product candidates. Our first-generation trachea technology was used in five adult human trachea transplants approved under compassionate use exemptions, but none of our products are yet approved for marketing by a government regulatory authority.

Twitter:  Investor Relations @HART_IR_Team 
StockTwits: @HART_IR

Contact:
Catalyst Global LLC
David Collins, Tanya Kamatu
212-924-9800
hart@catalyst-ir.com

Logo - http://photos.prnewswire.com/prnh/20151110/286060LOGO

 


'/>"/>
SOURCE Harvard Apparatus Regenerative Technology, Inc.
Copyright©2015 PR Newswire.
All rights reserved


Related biology technology :

1. The EQUITY Series of Business/Medical Thrillers by Award-winning Author Rudy Mazzocchi, Continue to Climb the Charts
2. Chemical Publishing Company to Release New Title Boiler Water Treatment Principles and Practice: Charts and Notes for Field Use
3. Bayer CropScience Charts Course For Cultivating Bee Health Solutions With Opening Of Clayton Bee Care Facility
4. Princeton report charts a step-by-step path toward a nuclear weapons-free Middle East
5. Infinata's BioPharm Insight Global Editor Kim Ha to Moderate Panel at 3rd Annual U.S.-China Conference on Strategies for Mining Profits from Pharma Opportunities in China
6. Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
7. Favorable Demographics Will Drive Moderate Expansion In The US Market For Skin Replacements And Substitutes
8. Ember Therapeutics Announce Initial Positive Results From a Phase 2 Trial of BMP-7 in Patients with Moderate Osteoarthritis of the Knee
9. Moderate Drinkers Who Abstain for Even a Short Time Reduce Risk Factors for Non-alcoholic Fatty Liver Disease
10. Dominion Diagnostics to Sponsor 2013 Addiction Professional Panel Series as Thought Leadership Partner
11. Dyadic International To Speak At Advanced Biofuels Leadership Conference Panel Discussion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/4/2019)... ... 2019 , ... Calidi Biotherapeutics, Inc., a clinical-stage ... the founding of a scientific and medical advisory board (SMAB). The SMAB will ... the Immuno-Oncology field. The founding members of Calidi Biotherapeutics SMAB include Lisa H. ...
(Date:12/19/2018)... ... December 19, 2018 , ... R3 ... rate Stem Cell Training Course in Las Vegas. Training includes facial rejuvenation, hair ... explode in popularity nationwide for aesthetics, having the training from expert, Board Certified ...
(Date:12/18/2018)... ... December 17, 2018 , ... ABCT , the ... ventures invited to participate in the annual program. Twelve ventures will participate in ... a professional network. All startups receive an entrepreneur coach, access to active business ...
(Date:12/18/2018)... LOMA LINDA, Calif. (PRWEB) , ... December 18, 2018 , ... ... treatment after a lumpectomy have better quality of life post-treatment versus whole breast irradiation, ... to two — are typically treated with whole breast irradiation after removal of the ...
Breaking Biology Technology:
(Date:12/18/2018)... ... December 18, 2018 , ... CP Merritt is a national ... competing for many years however in 2006, he had a medical setback that caused ... determined that he suffered from cartilage degeneration in his right rear fetlock. Such ...
(Date:12/13/2018)... ... 12, 2018 , ... Royal Biologics, an ortho-biologics company who ... launch of Maxx-Cell, the world's most advanced bone marrow aspiration device. , Maxx™-Cell ... autologous bone marrow cells. Maxx™-Cell however does not require centrifugation to deliver a ...
(Date:12/10/2018)... ... December 10, 2018 , ... Nanomedical Diagnostics , leading producer of ... Towne Centre Drive, Suite 100, effectively tripling its space from 5,200 to 16,500 square ... for the sales of our drug discovery platforms. We’re in the great position of ...
Breaking Biology News(10 mins):